{"id":"xbb-1-5-adapted-vaccinated","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ibuprofen","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pain relievers","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Herbal supplements","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ginkgo biloba","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fish oil","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Vitamin E","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Corticosteroids","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Immunosuppressants","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Live vaccines","action":"Avoid","effect":"Increased risk of infections"},{"drug":"Interferons","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Biologics","action":"Monitor","effect":"Increased risk of infections"}],"commonSideEffects":[],"contraindications":["Individuals who are hypersensitive to the active ingredient or to any ingredients in the formulation, including any non-medicinal ingredient, or component of the container."],"specialPopulations":{"Pregnancy":"pregnancy at study inclusion or during participation","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"patients with liver cirrhosis, liver transplantation, hepatic cancer, and immunosuppression"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=xbb-1-5-adapted-vaccinated","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:37:20.745474+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:37:27.818397+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:37:20.764829+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=xbb-1-5-adapted-vaccinated","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:37:29.038738+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Motilin receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:37:30.090660+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2110756/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:37:29.977266+00:00"}},"allNames":"xbb.1.5-adapted vaccinated","offLabel":[],"timeline":[],"aiSummary":"XBB.1.5-adapted vaccinated, developed by Pfizer Inc., is a marketed drug for COVID-19 prevention. It has generated $21.2B in revenue. The mechanism of action is not specified. This drug is a key player in the market for COVID-19 prevention. Its clinical differentiation and commercial significance are notable. There are no pipeline developments mentioned.","brandName":"XBB.1.5-adapted vaccinated","ecosystem":[],"isGeneric":true,"mechanism":{"target":"unknown","novelty":"unknown","modality":"unknown","drugClass":"unknown","explanation":"","oneSentence":"","technicalDetail":"The exact mechanism of action for XBB.1.5-adapted vaccinated is not specified, but it is likely to involve the targeting of specific molecular pathways involved in COVID-19 prevention. This may include the inhibition of viral replication or the enhancement of the immune response. Further research is needed to confirm the exact mechanism."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=xbb-1-5-adapted-vaccinated","fields":["publications"],"source":"PubMed/NCBI"},{"id":2,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":3,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":4,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:37:32.776289+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"BNT162b2 XBB.1.5-adapted","company":"Pfizer Inc.","advantage":"86.1% more likely to be effective against XBB-related infection than the mRNA-1273 XBB.1.5-adapted vaccine"},{"name":"mRNA-1273 XBB.1.5-adapted","company":"Pfizer Inc.","advantage":"82.2% more likely to prevent COVID-19-related hospitalization than BNT162b2 XBB.1.5-adapted vaccines"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"better than mRNA-1273 XBB.1.5-adapted monovalent vaccines"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"similar protection against XBB-related hospitalization, infection, and medically attended visits"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"36% efficacy against XBB-related COVID-19 infection"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"16% efficacy against COVID-19-related hospitalization"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"similar efficacy against COVID-19-related hospitalization"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"86.1% more likely to be effective against XBB-related infection than the mRNA-1273 XBB.1.5-adapted vaccine"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"82.2% more likely to prevent COVID-19-related hospitalization than BNT162b2 XBB.1.5-adapted vaccines"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"better than mRNA-1273 XBB.1.5-adapted monovalent vaccines"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"similar protection against XBB-related hospitalization, infection, and medically attended visits"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"36% efficacy against XBB-related COVID-19 infection"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"16% efficacy against COVID-19-related hospitalization"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"similar efficacy against COVID-19-related hospitalization"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"86.1% more likely to be effective against XBB-related infection than the mRNA-1273 XBB.1.5-adapted vaccine"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"82.2% more likely to prevent COVID-19-related hospitalization than BNT162b2 XBB.1.5-adapted vaccines"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"better than mRNA-1273 XBB.1.5-adapted monovalent vaccines"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"similar protection against XBB-related hospitalization, infection, and medically attended visits"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"36% efficacy against XBB-related COVID-19 infection"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"16% efficacy against COVID-19-related hospitalization"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"similar efficacy against COVID-19-related hospitalization"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"86.1% more likely to be effective against XBB-related infection than the mRNA-1273 XBB.1.5-adapted vaccine"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"82.2% more likely to prevent COVID-19-related hospitalization than BNT162b2 XBB.1.5-adapted vaccines"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"better than mRNA-1273 XBB.1.5-adapted monovalent vaccines"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"similar protection against XBB-related hospitalization, infection, and medically attended visits"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"36% efficacy against XBB-related COVID-19 infection"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"16% efficacy against COVID-19-related hospitalization"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"similar efficacy against COVID-19-related hospitalization"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"86.1% more likely to be effective against XBB-related infection than the mRNA-1273 XBB.1.5-adapted vaccine"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"82.2% more likely to prevent COVID-19-related hospitalization than BNT162b2 XBB.1.5-adapted vaccines"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"better than mRNA-1273 XBB.1.5-adapted monovalent vaccines"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"similar protection against XBB-related hospitalization, infection, and medically attended visits"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"36% efficacy against XBB-related COVID-19 infection"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"16% efficacy against COVID-19-related hospitalization"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"similar efficacy against COVID-19-related hospitalization"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"86.1% more likely to be effective against XBB-related infection than the mRNA-1273 XBB.1.5-adapted vaccine"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"82.2% more likely to prevent COVID-19-related hospitalization than BNT162b2 XBB.1.5-adapted vaccines"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"better than mRNA-1273 XBB.1.5-adapted monovalent vaccines"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"similar protection against XBB-related hospitalization, infection, and medically attended visits"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"36% efficacy against XBB-related COVID-19 infection"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"16% efficacy against COVID-19-related hospitalization"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"similar efficacy against COVID-19-related hospitalization"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"86.1% more likely to be effective against XBB-related infection than the mRNA-1273 XBB.1.5-adapted vaccine"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"82.2% more likely to prevent COVID-19-related hospitalization than BNT162b2 XBB.1.5-adapted vaccines"},{"name":"BNT162b2 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"better than mRNA-1273 XBB.1.5-adapted monovalent vaccines"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"similar protection against XBB-related hospitalization, infection, and medically attended visits"},{"name":"mRNA-1273 XBB.1.5-adapted monovalent vaccines","company":"Pfizer Inc.","advantage":"36% efficacy against XBB-related COVID-19 infection"}],"genericName":"xbb-1-5-adapted-vaccinated","indications":{"approved":[{"name":"COVID-19 prevention","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"","name":"XBB.1.5-adapted vaccinated","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL2110756","moleculeType":"Small molecule","molecularWeight":"755.99"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2110756"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Vaccine","firstApprovalDate":"","enrichmentLevel":3,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:37:32.776289+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}